» Articles » PMID: 30304861

Targeted Theranostic Nanoparticles for Brain Tumor Treatment

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2018 Oct 12
PMID 30304861
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

The poor prognosis and rapid recurrence of glioblastoma (GB) are associated to its fast-growing process and invasive nature, which make difficult the complete removal of the cancer infiltrated tissues. Additionally, GB heterogeneity within and between patients demands a patient-focused method of treatment. Thus, the implementation of nanotechnology is an attractive approach considering all anatomic issues of GB, since it will potentially improve brain drug distribution, due to the interaction between the blood⁻brain barrier and nanoparticles (NPs). In recent years, theranostic techniques have also been proposed and regarded as promising. NPs are advantageous for this application, due to their respective size, easy surface modification and versatility to integrate multiple functional components in one system. The design of nanoparticles focused on therapeutic and diagnostic applications has increased exponentially for the treatment of cancer. This dual approach helps to understand the location of the tumor tissue, the biodistribution of nanoparticles, the progress and efficacy of the treatment, and is highly useful for personalized medicine-based therapeutic interventions. To improve theranostic approaches, different active strategies can be used to modulate the surface of the nanotheranostic particle, including surface markers, proteins, drugs or genes, and take advantage of the characteristics of the microenvironment using stimuli responsive triggers. This review focuses on the different strategies to improve the GB treatment, describing some cell surface markers and their ligands, and reports some strategies, and their efficacy, used in the current research.

Citing Articles

Advances in the Repurposing and Blood-Brain Barrier Penetrance of Drugs in Pediatric Brain Tumors.

Rechberger J, Toll S, Biswas S, You H, Chow W, Kendall N Cancers (Basel). 2025; 17(3).

PMID: 39941807 PMC: 11816256. DOI: 10.3390/cancers17030439.


Therapeutic targeting of obesity-induced neuroinflammation and neurodegeneration.

Zeng J, Cheong L, Lo C Front Endocrinol (Lausanne). 2025; 15:1456948.

PMID: 39897964 PMC: 11781992. DOI: 10.3389/fendo.2024.1456948.


Microbeam Radiation Therapy Bio-Dosimetry Enhanced by Novel Radiosensitiser Combinations in the Treatment of Brain Cancer.

Valceski M, Engels E, Vogel S, Paino J, Potter D, Hollis C Cancers (Basel). 2025; 16(24.

PMID: 39766130 PMC: 11674565. DOI: 10.3390/cancers16244231.


Engendered nanoparticles for treatment of brain tumors.

Soleymani S, Doroudian M, Soezi M, Beladi A, Asgari K, Mobarakshahi A Oncol Res. 2024; 33(1):15-26.

PMID: 39735671 PMC: 11671406. DOI: 10.32604/or.2024.053069.


Deep learning-based deformable image registration with bilateral pyramid to align pre-operative and follow-up magnetic resonance imaging (MRI) scans.

Zhang J, Xie X, Cheng X, Li T, Zhong J, Hu X Quant Imaging Med Surg. 2024; 14(7):4779-4791.

PMID: 39022247 PMC: 11250335. DOI: 10.21037/qims-23-1821.


References
1.
Kobayashi K, Ohnishi A, Promsuk J, Shimizu S, Kanai Y, Shiokawa Y . Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery. 2008; 62(2):493-503. DOI: 10.1227/01.neu.0000316018.51292.19. View

2.
Gupta A, Gupta M . Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005; 26(18):3995-4021. DOI: 10.1016/j.biomaterials.2004.10.012. View

3.
Hamilton J, Brunaldi K . A model for fatty acid transport into the brain. J Mol Neurosci. 2007; 33(1):12-7. DOI: 10.1007/s12031-007-0050-3. View

4.
Ma X, Zhao Y, Liang X . Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc Chem Res. 2011; 44(10):1114-22. DOI: 10.1021/ar2000056. View

5.
Taylor T, Furnari F, Cavenee W . Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets. 2012; 12(3):197-209. PMC: 3464093. DOI: 10.2174/156800912799277557. View